Literature DB >> 6425363

Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man.

L A Frohman, J L Thominet, C B Webb, M L Vance, H Uderman, J Rivier, W Vale, M O Thorner.   

Abstract

The metabolic clearance rate (MCR) and plasma disappearance rate (t1/2) of human pancreatic tumor growth hormone releasing factor [hpGRF(1-40)] was determined in normal adult male subjects by single injection and constant infusion techniques. Single injections of 1, 3.3, and 10 micrograms/kg hpGRF(1-40) were administered intravenously, plasma immunoreactive (IR) GRF levels were measured during the subsequent 180 min, and biexponential curve analysis was performed. Graded, dose-constant infusions of hpGRF(1-40) at rates of 1, 3.3, 10, and 33 ng/kg per min were administered and the MCR was calculated from measurement of steady state plasma IR-GRF levels at each infusion rate. The postinfusion disappearance rate was determined by linear regression analysis of plasma IR-GRF levels during the 120-min period after cessation of the infusion. The calculated MCR during the single injection study was 194 +/- 17.5 liters/m2 per d and was not significantly different from the calculated value during the constant infusion study (202 +/- 16 liters/m2 per d). The disappearance rate during the single injection study was subdivided into two linear phases: an initial equilibration phase (7.6 +/- 1.2 min) and a subsequent elimination phase (51.8 +/- 5.4 min). The latter was similar to the linear disappearance rate observed (41.3 +/- 3.0 min) after cessation of the constant infusion. The chromatographic and biologic characteristics of plasma IR-GRF, 30 min after injection, were similar to those of synthetic hpGRF(1-40). The results have been discussed in relation to the MCR of other hypothalamic hormones and have been used to extrapolate secretion rates of GRF in patients with ectopic GRF production.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6425363      PMCID: PMC425152          DOI: 10.1172/JCI111333

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

Review 1.  REVIEW: THE USE OF ISOTOPIC STEROIDS FOR THE MEASUREMENT OF PRODUCTION RATES IN VIVO.

Authors:  J F TAIT
Journal:  J Clin Endocrinol Metab       Date:  1963-12       Impact factor: 5.958

2.  Growth hormone and insulin levels in weanling rats with ventromedial hypothalamic lesions.

Authors:  L A Frohman; L L Bernardis
Journal:  Endocrinology       Date:  1968-06       Impact factor: 4.736

3.  Somatostatin-like immunoactivity and biological activity is present in Tetrahymena pyriformis, a ciliated protozoan.

Authors:  M Berelowitz; D LeRoith; H von Schenk; C Newgard; M Szabo; L A Frohman; J Shiloach; J Roth
Journal:  Endocrinology       Date:  1982-06       Impact factor: 4.736

4.  Characterization of a 40 residue peptide from a human pancreatic tumor with growth hormone releasing activity.

Authors:  F S Esch; P Böhlen; N C Ling; P E Brazeau; W B Wehrenberg; M O Thorner; M J Cronin; R Guillemin
Journal:  Biochem Biophys Res Commun       Date:  1982-11-16       Impact factor: 3.575

5.  Elimination of TRH in man.

Authors:  J Leppaluoto; P Virkkunen; H Lybeck
Journal:  J Clin Endocrinol Metab       Date:  1972-09       Impact factor: 5.958

6.  Extraction of somatostatin from human plasma on octadecylsilyl silica.

Authors:  B Vasquez; V Harris; R H Unger
Journal:  J Clin Endocrinol Metab       Date:  1982-10       Impact factor: 5.958

7.  Acromegaly associated with a bronchial carcinoid tumor: evidence for ectopic production of growth hormone-releasing activity.

Authors:  M Saeed uz Zafar; R C Mellinger; G Fine; M Szabo; L A Frohman
Journal:  J Clin Endocrinol Metab       Date:  1979-01       Impact factor: 5.958

8.  Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man.

Authors:  W E Nicholson; G S DeCherney; R V Jackson; C R DeBold; H Uderman; A N Alexander; J Rivier; W Vale; D N Orth
Journal:  J Clin Endocrinol Metab       Date:  1983-12       Impact factor: 5.958

9.  Immunohistochemical detection of growth hormone-releasing factor in brain.

Authors:  B Bloch; P Brazeau; N Ling; P Bohlen; F Esch; W B Wehrenberg; R Benoit; F Bloom; R Guillemin
Journal:  Nature       Date:  1983 Feb 17-23       Impact factor: 49.962

10.  Characterization of rat hypothalamic growth hormone-releasing factor.

Authors:  J Spiess; J Rivier; W Vale
Journal:  Nature       Date:  1983 Jun 9-15       Impact factor: 49.962

View more
  10 in total

1.  Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus.

Authors:  L A Frohman; T R Downs; T C Williams; E P Heimer; Y C Pan; A M Felix
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

Review 2.  The Gordon Wilson Lecture. Growth hormone replacement in adults and other uses.

Authors:  M L Vance
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

Review 3.  Regulation of growth hormone secretion in man: a review.

Authors:  D G Johnston; R R Davies; R W Prescott
Journal:  J R Soc Med       Date:  1985-04       Impact factor: 5.344

4.  Pharmacokinetics of human growth hormone releasing factor (hGRF-44 NH2) in normal men after intravenous administration of a large range of doses.

Authors:  P Girard; R Cohen; G Sassolas; C Harthe; P Cabrera; J P Boissel
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Octreotide therapy of growth hormone excess in the McCune-Albright syndrome.

Authors:  S I Sherman; P W Ladenson
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

6.  Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma.

Authors:  L A Frohman; T R Downs; E P Heimer; A M Felix
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

7.  Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. Intermittent secretion or response attenuation.

Authors:  C B Webb; M L Vance; M O Thorner; G Perisutti; J Thominet; J Rivier; W Vale; L A Frohman
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

8.  Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.

Authors:  M L Vance; D L Kaiser; W S Evans; R Furlanetto; W Vale; J Rivier; M O Thorner
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

9.  Corticotropin- and growth hormone-releasing factor (CRF and GRF) in the diagnosis of hypothalamo-pituitary diseases.

Authors:  K von Werder; O A Müller
Journal:  Neurosurg Rev       Date:  1985       Impact factor: 3.042

Review 10.  Regulation of growth hormone-releasing hormone gene expression and biosynthesis.

Authors:  L A Frohman; T R Downs; P Chomczynski; A Brar; Y Kashio
Journal:  Yale J Biol Med       Date:  1989 Sep-Oct
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.